Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2) research hub

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

This study looks at how new medicines for diabetes and weight management, called Rybelsus and Wegovy, might affect tiny cells in your blood called platelets. We want to see if these medicines change how sticky platelets are in people with diabetes, who are overweight, or who have heart disease, as sticky platelets can cause problems.